Compare WYY & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WYY | MNOV |
|---|---|---|
| Founded | 1991 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.3M | 137.8M |
| IPO Year | 2005 | 2004 |
| Metric | WYY | MNOV |
|---|---|---|
| Price | $7.77 | $1.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 357.9K | ★ 792.7K |
| Earning Date | 08-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $150,545,364.00 | $2,360,807.00 |
| Revenue This Year | $12.26 | $78.20 |
| Revenue Next Year | $25.66 | N/A |
| P/E Ratio | $746.23 | ★ N/A |
| Revenue Growth | 5.59 | ★ 194.15 |
| 52 Week Low | $3.96 | $1.17 |
| 52 Week High | $24.30 | $3.90 |
| Indicator | WYY | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 39.77 | 40.69 |
| Support Level | $4.46 | $1.28 |
| Resistance Level | $12.69 | $3.90 |
| Average True Range (ATR) | 1.23 | 0.37 |
| MACD | -0.46 | -0.14 |
| Stochastic Oscillator | 40.88 | 1.56 |
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.